• 10.18.17

    Criminal Charges, Civil Fines for Bitcoin Exchange and Operator

    By John F. Libby, Partner, Corporate Investigations and White Collar Defense | Jacqueline C. Wolff, Partner, Corporate Investigations and White Collar Defense | Kenneth B. Julian, Partner, LitigationWhy it matters: On July 26, 2017, the Department of Justice (DOJ) announced that a grand jury in the ...

  • 07.31.17

    Spotlight on the False Claims Act

    By John F. Libby, Partner, Corporate Investigations and White Collar Defense | Jacqueline C. Wolff, Partner, Corporate Investigations and White Collar Defense | Kenneth B. Julian, Partner, LitigationWhy it matters: Since our last newsletter, the DOJ has announced numerous resolutions under the ...

  • 06.28.17

    Spotlight on the False Claims Act June 2017

    By John F. Libby, Partner | Jacqueline C. Wolff, Partner | Kenneth B. Julian, PartnerWhy it matters: On May 30, 2017, the Department of Justice announced that Medicare Advantage Organization (MAO) Freedom Health Inc. and nine of its related entities, as well as its former chief operating officer, ...

  • 05.30.17

    Spotlight on the False Claims Act May 2017

    By Kenneth B. Julian, Partner | John F. Libby, Partner | Jacqueline C. Wolff, PartnerWhy it matters: Pronouncements by DOJ officials in April 2017 signaled that the DOJ will be "business as usual" with respect to pursuing white collar crime, including the False Claims ...

  • 03.07.16

    FCPA and AML Enforcement Review—"Follow the Money:" Liberty Case Review

    This month we highlight three recent instances where the federal enforcement agencies have announced settlements, prosecutions and orders in their continued efforts to "follow the money" down the twin rabbit holes of bribes payments and money laundering. The SEC announced settlements in ...

  • 09.28.15

    The FCA and Overpayments: 'Kane' Creates New Risks for Healthcare Providers

    Healthcare providers that treat Medicare and Medicaid patients regularly face a quandary: What should they do when faced with the possibility that they may have been overpaid by the government for their services? Overpayments could result from innocent coding errors stemming from confusion over ...

  • 08.19.15

    Guarding Against Bribery When Conducting Clinical Trials Overseas

    Clinical trials sponsored by pharmaceutical and medical device companies are generally intended to obtain data to support applications to the FDA for the approval of new drugs or devices or the approval of new indications or uses for currently marketed drugs or devices. In an effort to cut down ...

  • 08.05.15

    Can Cooperation Expose a Company to a Defamation Claim?

    When faced with allegations of wrongdoing, companies and their outside counsel generally will conduct their own investigation and report their findings to the government. In the past, such a presentation of the facts and evidence tended to be viewed as cooperation, but the government now expects ...

  • 07.01.14

    General Schemes vs. Specific Claims

    The qui tam provisions of the False Claims Act, which allow private individuals ("relators") to bring suit on behalf of the federal government and keep a percentage of the proceeds, continue to be some of the most potent weapons in the government's antifraud arsenal. In fiscal year 2013, over ...

  • 06.01.13

    Navigating the FCPA in Healthcare and Life Sciences

    In 2012, companies and executives operating in the healthcare and life sciences industries had an outsize presence in Foreign Corrupt Practices Act (FCPA) enforcement actions. Given recent Department of Justice (DOJ) and Securities and Exchange Commission (SEC) pronouncements, coupled with more ...

manatt-black

ATTORNEY ADVERTISING

pursuant to New York DR 2-101(f)

© 2021 Manatt, Phelps & Phillips, LLP.

All rights reserved